Systemic lupus erythematosus happens when the body’s immune system, which protects the body by fighting sickness, stops working correctly. As an SLE patient, you know all about the physical problems SLE can cause. This can include fatigue, headaches, joint pain, joint swelling, and a rash on the cheeks and nose called a butterfly rash.
The SOAR study is looking at whether a study medication, combined with your existing SLE treatment, may help better control your SLE symptoms. The study drug is a prescription medication approved in the U.S. by the Food and Drug Administration (FDA) for use during a worsening or an increase in severity of SLE symptoms, or in select cases, as a maintenance treatment for SLE. It is not approved for use in any other countries.
To qualify for this research study, you must:
- Have symptoms of SLE
- Be 18 years of age or older
- Have rash and/or arthritis caused by your SLE
- Be currently taking prednisone (or prednisone equivalent)
- Not have diabetes
Eligible participants will receive the study medication and study-related care at no cost. While in the study, all patients will also continue to take their current SLE medications.